Market Access Granted In Italy For Aggressive Non-Hodgkin Lymphoma ... Daily Markets (press release) CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the United States. About Non-Hodgkin Lymphoma. Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive ... |
